Leadership Team

Meet iSpecimen's experienced leadership team with a shared commitment to our mission.

Tracy Wilson Curley

Interim Chief Executive Officer & Chief Financial Officer

Tracy is an experienced, results-oriented business builder focused on leading iSpecimen’s vision for progressive financial performance, expansion and growth in today’s dynamic healthcare and biotechnology research markets.

Tracy brings three decades of experience in public accounting and corporate finance for both publicly traded companies and emerging companies like iSpecimen. Before joining iSpecimen, Tracy served as a partner at CohnReznick LLP, a national accounting firm, where she led the creation and development of an emerging markets commercial audit practice team focused on recruiting and providing audit services to private and public emerging growth companies in the technology and life sciences industries. Earlier, and as a partner at Marcum LLP, a national accounting firm, Tracy led the northeast regional high-tech practice for the firm with a focus on expanding the client base to provide a full range of accounting, tax and advisory services for private and public emerging growth companies in high tech industries such as technology, life sciences and advanced manufacturing. Tracy has also served as a partner at Moody, Famiglietti & Andronico, LLP (MFA), a proactive, Boston-based consulting firm with national and global reach, where she led the creation and development of a public company audit practice focused on recruiting and providing audit services to public emerging growth companies.

Tracy received her Master of Accountancy and Bachelor of Science in Business Administration with a concentration in accounting from Kansas State University. She also attended the United States Military Academy. She is a certified public accountant licensed in the Commonwealth of Massachusetts.

Tracy Wilson Curley

Chief Executive Officer

Read Bio

Leslie Hoyt

Senior Vice President of Operations

Leading Operations for iSpecimen, Leslie utilizes her 30+ years as a COO in healthcare, and focuses on operational efficiency, change management, and building strong relationships in and out of the company. She is responsible for the teams of professionals working on order fulfillment, supplier relationships, laboratory and distribution services, customer service, and human resources.

Leslie started her career on the provider-side of healthcare. As COO of the CareGroup PSN, the value-based contracting organization for 9 major hospitals and their physicians, she built cross hospital programs to improve the quality of care and ensure financial success in a capitated environment.

As VP and US Healthcare practice lead at Sapient (now Publicis Sapient), a Global IT consultancy, her passion for leveraging technology to improve the quality of healthcare was realized. She used that experience in technology and business to design and manage Dovetail Health, a healthcare technology company addressing home-based medication adherence following high-risk admissions, which was ultimately sold to Optum. As SVP of Optum, Leslie managed major strategic partners, leveraging UHG assets to create innovative health solutions that benefited both parties.

Leslie excels in start-up, high growth settings, and more recently has been a COO for biotech companies in the Boston area such as GNS (now Aitia), Olaris, and Naveris.

Leslie lives in Lexington, MA and enjoys playing tennis, pickleball and golf.

Leslie Hoyt

Senior Vice President of Operations

Read Bio

Evan Cox

Vice President of Product Management

Evan brings nearly 20 years of Product Management and leadership experience to iSpecimen. In his role at iSpecimen, Evan is responsible for creation and management of the long-term roadmap and strategy plan for our industry leading iSpecimen Marketplace application. Prior to joining iSpecimen, Evan held several key senior management roles at Definitive Healthcare Corp., a provider of healthcare commercial intelligence, most recently as Associate Vice President, where he led the product management team. Before that, he held multiple product strategy and decision support roles at Change Healthcare, a healthcare technology company, where he focused on artificial intelligence and natural language processing to streamline existing workflows.

In addition, Mr. Cox co-founded DSE Analytics, a company that used natural language processing to integrate qualitative and quantitative information available on Consumer Assessment of Healthcare Providers and Systems (CAHPS) surveys to deliver providers deep insights into their satisfaction scores. He also served as Senior Product Manager of Data Analytics and Research at Press Ganey Associates and Product Lead of Clinical Data Management at WebMD.

Evan Cox

Senior Vice President of Strategy & Innovation

Read Bio

Brielan Smiechowski

Senior Vice President of Business Development

Brielan leads iSpecimen's business development and sales. She and her team are focused on helping scientists and their organizations procure the biospecimens necessary to advance their research and technologies.

Brielan Smiechowski brings over 15 years of experience in Life Sciences and Healthcare. She is a technical advisor for the City of Gloucester Health Department and lectures at the University of Southern California. She is a partner with Social Justice Partners Los Angeles and a board member of the nonprofit Eat Move Meditate. Previously, Brielan was a director at Veeva and has also held business development and research roles at HealthVerity, Aitia, PrecisionAQ, and Icon PLC. Brielan received her MSc in Epidemiology from McGill University and BS in Biological Sciences from Arkansas State University.

Brielan Smiechowski

Senior Vice President of Business Development

Read Bio

Annette Arnold

Vice President of Sales & Business Development

Annette is responsible for driving and managing all aspects of company sales and business development. In this position, she applies her strategic vision as well as her skills in negotiation, facility management (FM) and management. Additionally, she plays a key role in analyzing and developing the supply partner network in order to meet the demands of iSpecimen’s rapidly expanding customer base.

Annette has over 20 years of experience working in sales. Before joining iSpecimen, Annette was Manager of Business Development at Folio Conversant. There, she was responsible for supporting and growing business within existing accounts, and developing new accounts, through direct customer sales. Prior to Folio Conversant, she moved from Business Administrator to Client Account Manager at Biblioteca. For over a decade, Annette and her teams have established solid relationships with R&D groups, grown business revenue substantially, and streamlined project workflows for vital accounts. Annette holds an AS in Computer Science from Keene State College.

Annette Arnold

Vice President of Sales & Business Development

Read Bio

Carly Lejnieks

Vice President of Marketing

Carly and her team are focused on bringing the unique iSpecimen offering to life science customers who are seeking streamlined, compliant solutions for procuring archived pathology, banked, and prospective or custom-collected human biospecimens. The team is also focused on engaging new partners interested in joining the iSpecimen network, enabling deep and far-reaching access to millions of human biospecimens and patients that have consented to donate them.

Carly has led marketing strategies, integrated programs, and high-growth initiatives for Life Science organizations for more than 20 years. Before joining iSpecimen, she worked as a marketing consultant for more than a decade serving clients in the healthcare and life science industries. Most recently, she managed global, digital marketing and eCommerce programs responsible for driving double-digit growth in the cell culture consumables division of Thermo Fisher Scientific.

Carly Lejnieks

Vice President of Marketing

Read Bio

Board of Directors

The following individuals sit on iSpecimen's board of directors

Elizabeth Graham

Board Member

Elizabeth A. Graham has been serving as our director since March 21, 2024. Ms. Graham has extensive experience in advising and investing in early-stage technology companies. Currently, she also serves on the board of MassChallenge, a global startup accelerator since September 2023 and is on the advisory board of the Rappaport Institute for Greater Boston at the Harvard Kennedy School since March 2023. Previously, from December 2020 to March 2024, Ms. Graham served as the Chief Operating Officer at Indigo Ag. Inc., a sustainable agriculture technology company. From March 2022 to August 2023, Ms. Graham served as the director and the chair or member of Compensation Committee, Nominating and Governance Committee, and Audit Committee, of Starry Holdings Group, Inc., an internet service company. Prior to that, she was the president of Notarize, Inc., a remote online notarization company, from January 2020 to May 2020, where she initially joined as the Chief Operating Officer in January 2019. She also served as the Vice President of Global Sales and Service at Wayfair LLC, a global e-commerce home furnishings company, from May 2015 to December 2018. Prior to her roles in the technology industry, Ms. Graham had approximately thirteen years of experience in the cable and telecommunications industry. Ms. Graham holds an A.B. from Harvard College, an M.St. from the University of Oxford, England, and a J.D. from Harvard Law School. Ms. Graham is well-qualified to serve on the Board due to her extensive management experience in ecommerce, developing marketplaces, and scaling technology companies.

Elizabeth Graham

Board Member

Read Bio

Theresa (Terri) Mock

Board Member

Theresa L. Mock has been serving as our director since May 2023. Ms. Mock has extensive experience in the software and technology industries with expertise in market strategy, revenue growth, and commercial operations. Since September 2022, Ms. Mock has been an independent consultant for software and technology companies. From January 2020 to April 2022, she served as the Chief Strategy and Marketing Officer at Rave Mobile Safety, a SaaS mass notification and incident management company. From September 2017 to December 2019, Ms. Mock served as the Chief Operating Officer at Cybba, Inc., and from January 2015 to August 2017, she served as Chief Revenue Officer at Ve Interactive North America, both digital marketing and advertising agencies. She previously held senior management roles in global software and technology companies at Deltek from November 2011 to December 2014, and OpSec Security from June 2007 to October 2011. Ms. Mock served as a board director at G3 VRM Acquisition Corp. (NASDAQ: GGGV) from April 2021 to July 2022. She currently serves on the non-profit boards of the Boston Chinatown Neighborhood Center since January 2018, and The Boston Club since January 2017. Ms. Mock received her BS and MS in Chemical Engineering from the Massachusetts Institute of Technology, and her MBA from the MIT Sloan School of Management. Ms. Mock is well-qualified to serve on the Board due to her extensive management experience in the software and technology industries.

Theresa Mock

Board Member

Read Bio

Steven Gullans

Board Member

Steven Gullans, Director has been serving as our director since October 2020. From May 2018 to December 2019, he served as President and Chief Executive Officer and Director of Gemphire Therapeutics, until it was acquired by NeuroBo Pharmaceuticals. While at Gemphire, he oversaw activities related to clinical trials, manufacturing, finances, business development, R&D and intellectual property. Prior to Gemphire, he was Managing Director at Excel Venture Management, LLC (“Excel”), a Boston-based venture capital firm which he co-founded, from March 2008 to May 2018.

At Excel, he focused on investing in life science technology companies with a particular interest in disruptive platforms that can impact multiple industries. Prior to Excel, Dr. Gullans co-founded RxGen, Inc., a pharmaceutical services company, where he also served as Chief Executive Officer and a director from February 2004 to February 2008. Prior to that, he was the Chief Scientific Officer of US Genomics, Inc., a company that develops technology to analyze DNA for pathogen detection, from November 2002 to January 2004. Dr. Gullans serves as a director at Orionis Biosciences, a drug development company.

He was previously a board member of Activate Networks, Inc. which was acquired by Decision Resource Group, nanoMR Inc., which was acquired by DNA Electronics Ltd, Tetraphase Pharmaceuticals, Inc. which went public in 2013, and Molecular Templates, Inc. which was merged into a public entity in 2017. Dr. Gullans was a faculty member at Harvard Medical School and Brigham and Women’s Hospital for almost 20 years. Dr. Gullans holds a B.S. from Union College and a Ph.D. from Duke University. He is well-qualified to serve on our Board due to his extensive experience in biopharmaceutical industries and his expertise in medical and pharmaceutical research.

Steven Gullans

Board Member

Read Bio

John L. Brooks III

Board Member

John L. Brooks III, a director nominee, will join our board of directors upon the effectiveness of the registration statement of which this prospectus forms a part. He currently also serves as a director of Hemoshear Therapeutics since November 2008, Noxilizer since March 2009, Hygieia since June 2016 and Atentiv since March 2020. He also serves as the chairman of Thermalin, Inc. since January 2009.

In January 2012, Mr. Brooks founded Ammonett Pharma and continues to serve on its board of directors since then. He has also served as the managing director of Healthcare Capital LLC since February 2007. Previously, Mr. Brooks served as the Chief Executive Officer, President and a director of NeuroBo Pharmaceuticals, Inc. from March 2018 to December 2019 and as the chairman of Cellnovo, Ltd. from 2012 to December 2019.

Mr. Brooks is also involved with several non-profit organizations. He currently serves as the Chief Executive Officer and President of Worldwide Network for Innovation in Clinical Education and Research (WNICER) since January 2019 and also serves as a director of T1D Exchange since March 2020, the ADA New England Chapter since January 2015, Population Health Alliance since January 2014, and the University of Massachusetts Amherst Foundation since January 2012.

He also chairs the College Diabetes Network since January 2011 and is also on the board of trustees of Suffolk University since March 2012. Mr. Brooks received his BBA and MSBA in Accounting from the University of Massachusetts Amherst. He is well-qualified to serve on our Board due to his expertise in healthcare and life sciences.

John L. Brooks III

Board Member

Read Bio

Tracy Curley

Board Member

Ms. Curley brings three decades of experience in public accounting and corporate finance for both publicly traded companies and emerging companies like iSpecimen and joined iSpecimen in August 2020. She came to iSpecimen after over a decade with national accounting firms such as CohnReznick where she focused on serving clients in the middle markets. During her time as a partner in public accounting firms, she was responsible for creating and leading teams to provide audit and consulting services to a growing clientele of private and public emerging growth companies primarily in the technology and life sciences industries. Ms. Curley received her Master of Accountancy and Bachelor of Science in Business Administration with a concentration in accounting from Kansas State University. She also attended the United States Military Academy. She is a certified public accountant licensed in the Commonwealth of Massachusetts

Tracy Curley

Board Member

Read Bio

Access our latest tissue and biofluids inventories, available for shipping now:

Leadership Team

Tracy Wilson Curley

Leslie Hoyt

Evan Cox

Brielan Smiechowski

Annette Arnold

Carly Lejnieks

Board of Directors

Elizabeth Graham

Theresa Mock

Steven Gullans

John L. Brooks III

Tracy Curley

Sample Providers

Patients

Company

Resources

Investors

Sign up to receive updates

Be a part of the biospecimen revolution

Researchers

Disease Focus

Human Biospecimens